December 29, 2017 / 11:19 AM / 9 months ago

BRIEF-Atara Biotherapeutics Gets FDA Clearance To Initiate Two Phase 3 Clinical Studies To Evaluate Tabelecleucel

Dec 29 (Reuters) - Atara Biotherapeutics Inc:

* ATARA BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE TO INITIATE TWO PHASE 3 CLINICAL STUDIES TO EVALUATE TABELECLEUCEL IN PATIENTS WITH RITUXIMAB-REFRACTORY EPSTEIN-BARR VIRUS ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (EBV+PTLD)

* ATARA BIOTHERAPEUTICS- RESULTS FROM FIRST TABELECLEUCEL PHASE 3 STUDY TO REACH PRIMARY ENDPOINT ARE EXPECTED TO BE ANNOUNCED IN FIRST HALF OF 2019

* ATARA-‍PLANS TO SUBMIT TABELECLEUCEL CMA APPLICATION IN EU FOR PATIENTS WITH RITUXIMAB-REFRACTORY EBV+PTLD POST HEMATOPOIETIC CELL TRANSPLANT IN H1 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below